Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Antibody > Glycoprotein E (VZV) > VZV-M545

Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) (MALS verified)

Order Now

  • Source
    Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) is a chimeric monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Glycoprotein E (VZV).
  • Isotype
    Human IgG1 | Human Kappa
  • Specificity
    This product is a specific antibody specifically reacts with Glycoprotein E (VZV).
  • Application
    ELISA
  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Endotoxin
    Less than 1.0 EU per mg by the LAL method.
  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS,pH 7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Glycoprotein E (VZV) SDS-PAGE

Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Glycoprotein E (VZV) MALS images

The purity of Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) (Cat. No. VZV-M545) is more than 95% and the molecular weight of this protein is around 135-155 kDa verified by SEC-MALS.

Bioactivity-Elisa
 Glycoprotein E (VZV) ELISA

Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) at 1 μg/mL (100 μL/well) can bind Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) (Cat. No. VZV-M545) with a linear range of 0.1-1 ng/mL (QC tested).

Bioactivity-SPR
 Glycoprotein E (VZV) SPR

Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) (Cat. No. VZV-M545) captured on Protein A Chip can bind Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) with an affinity constant of 4.81 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

  • Background
    Varicella-zoster virus (VZV) is a neurotropic virus belonging to the Herpesviridae family. Primary VZV infection causes chickenpox and is followed by a life-long latent infection established mainly in the cranial and dorsal root ganglia. Reactivation of the virus is often associated with shingles (herpes zoster). Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.The antibody can reacte with gE specially.
  • Clinical and Translational Updates

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $350.00

Price(USD) : $2310.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:2 Details
  • Latest Research Phase:Phase 1 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message